Sun Pharmaceutical Industries announced Q2FY23 results: Q2FY23: Gross sales at Rs. 108,092 million, growth of 13.1% over Q2 last year India formulation sales at Rs. 34,600 million, up 8.5% over Q2 last year US formulation sales at US$ 412 million, growth of 14.1% over Q2 last year Global specialty sales crossed US$ 200 million, growth of 27.5% over Q2 last year Emerging Markets formulation sales at US$ 259 million, up by 6.7% over Q2 last year Rest of World formulation sales at US$ 181 million, lower by about 3.8% over Q2 last year, impacted by adverse currency movements R&D; investments at Rs. 5,710 million compared to Rs. 5,364 million for Q2FY22 EBITDA at Rs. 29,565 million (including other operating revenues), up 12.4% YoY. EBITDA margin for Q2 at 27% versus 27.3% for Q2 last year Net profit for the quarter was at Rs. 22,622 million, up by 10.5% YoY, impacted by lower other income H1FY23: Gross sales at Rs. 214,532 million, growth of 11.6% over same period last year India formulation sales at Rs. 68,471 million, up 5.4% over same period last year US formulation sales at US$ 833 million, up by 12.4% over H1 last year Emerging Markets formulation sales at US$ 504 million up by 9.5% over H1 last year Rest of World formulation sales at US$ 371 million, marginally lower by 0.6% over H1 last year EBITDA at Rs. 58,409 million (including other operating revenues) up 7.2% over H1 last year, with resulting EBITDA margin of 26.9% Net profit for H1FY23 was at Rs. 43,231 million, up 23.8% YoY. Excluding the exceptional items of H1 last year, adjusted net profit was up by 7.4% Dilip Shanghvi, Managing Director of the Company said, “For Q2, we recorded double-digit topline growth and strong margins driven by market share gain in India, sustained ramp-up of our global specialty business and growth in Emerging Markets. Global specialty business has grown by 27.5% driven by Ilumya, Cequa and Winlevi. We continue to focus on expanding our global specialty business and growing all our businesses.” Result PDF